Ole Mathiesen

Impressive presentation today of the AID-ICU trial and research programme by @ARanberg at her Pd.h. defence at @SUHhospital @AndersPerner

Quick overview of the #AIDICU trial with important message in commentary - go read👇: acpjournals.org/doi/epdf/10.73…

Check out the current issue of @NEJM and find the AID-ICU trial supplemented with: --> Research summary --> Quick take video --> Interesting Editorial nejm.org/doi/full/10.10… @CRIC_Int_Care @MusaeusPoulsen @AndersPerner @ole_mathiesen

Kom og forsk hos os. Ph.d. studernee søges til Centre of Anaesthesiological Research, Anæstesiologisk Afdeling, Sjællands Universitetshospital, Køge via Sundhedsjobs.dk sundhedsjobs.dk/jobopslag/4392…

Here is our presentation and take of the AID-ICU trial. Read and share👍👍

9/9 #AIDICU trial was a massive teamwork Thanks to patients, relatives, clinicians, investigators, DMSC, monitors, admin staff and funders Coordinated by @ARanberg @BekkerCamilla @EstrupStine @CRIC_Int_Care Analyzed by: @LangeTheis Sponsor: @MusaeusPoulsen

8/9 How may clinicians use these results? Haloperidol is safe in ICU-pts with delirium and likely beneficial as 90-d mortality was lower in the haloperidol group The planned Bayesian analysis, long-term follow-up and systematic review of all trials will further inform decisions

6/9 Conclusion: Among acutely admitted, adult patients with delirium in the ICU, haloperidol did not result in more days alive and out of hospital at 90 days, but mortality was lower in the haloperidol group.

5/9 SAFETY: SAR in ICU Haloperidol: 11 (2.2%) Placebo: 9 (1.9%) Similar use of rescue medication in the two groups No statistically significant difference in days alive without delirium or coma, mechanical ventilation or use of rescue medication

4/9 DAOH day 90 Haloperidol: 35.8 days Placebo: 32.9 days Adj absolute MD 2.9 days; 95% CI, -1.2 to 7.0; P=0.22 Death day 90 Haloperidol: 182 pts (36.3%) Placebo: 210 pts (43.3%) Adj. absolute difference 6.9 %-points; 95% CI, −13.0 to -0.6

3/9 PT: 69 yrs, 33% F, 60% ventilated, 50% on pressors, predicted 90-d mortality 36%, hypoactive delirium 55%, hyperactive 45% Trial medication Haloperidol 8.3mg/day Placebo 9.0mg/day Cumulative dose Haloperidol 33mg Placebo 33mg Open-label antipsychotic 13% in both groups

2/9 P: 1000 acute adult ICU patients with delirium I: Haloperidol 2.5 mg x 3/d + as needed doses to max 20 mg/d while in delirium C: Placebo O: At 90 days... Days Alive and Out of Hospital Mortality Hospital LOS SAR Days Alive wo Delirium/Coma and wo Mechanical Ventilation

1/9 #AIDICU trial results on haloperidol vs. placebo for the treatment of delirium in ICU patients @NEJM Amazing work in 16 ICUs 🇩🇰🇫🇮🏴󠁧󠁢󠁷󠁬󠁳󠁿🇮🇹 Funded by @Innofond @regionsjaelland @regionerne nejm.org/doi/full/10.10…

Nu er det videnskabeligt bevist, at det er sikkert og uden alvorlige bivirkninger at behandle patienter med delir på intensiv med haloperidol - og med bedre overlevelse på 6.9 procentpoint. Tak til @ARanberg m.fl. for vigtig ny viden. nejm.org/doi/full/10.10…

Agree!! Thanks

But haloperidol did however lower all-cause mortality and appeared safe. IMO this study supports the use of haloperidol in patients with delirium in the ICU. Congratulations to the whole @CRIC_Int_Care group with the trial! #LIVES22 #CriticalCare

In this randomized trial, treatment with haloperidol did not increase the number of days alive and out of the hospital among ICU patients with delirium. #LIVES2022 nej.md/3VCuHMU

Today I presented the AID-ICU trial on behalf of the AID-ICU trial team at the @ESICM. We are proud to announce that the manuscript is now available online at NEJM: nejm.org/doi/full/10.10… @CRIC_Int_Care @SUHhospital @ole_mathiesen @AndersPerner @MusaeusPoulsen

Fantastisk præsentation af AID-ICU studiet ved Nina Andersen- Ranberg. Studiet er tilgængeligt på NEJMs hjemmeside. @MortenZiebell @SUHhospital @WurglerNiels @CRIC_Int_Care @AndersPerner

Proud to present the resultat of the AID-ICU trial that has just ben published i NEJM nejm.org/doi/full/10.10…